AU2019322325B2 - Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors - Google Patents

Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors Download PDF

Info

Publication number
AU2019322325B2
AU2019322325B2 AU2019322325A AU2019322325A AU2019322325B2 AU 2019322325 B2 AU2019322325 B2 AU 2019322325B2 AU 2019322325 A AU2019322325 A AU 2019322325A AU 2019322325 A AU2019322325 A AU 2019322325A AU 2019322325 B2 AU2019322325 B2 AU 2019322325B2
Authority
AU
Australia
Prior art keywords
carcinoma
cell
cancer
leu
brm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2019322325A
Other languages
English (en)
Other versions
AU2019322325A1 (en
Inventor
Christopher Adair
Katsumasa Nakajima
Rukundo Ntaganda
Julien Papillon
Troy Douglas SMITH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2019322325A1 publication Critical patent/AU2019322325A1/en
Application granted granted Critical
Publication of AU2019322325B2 publication Critical patent/AU2019322325B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2019322325A 2018-08-17 2019-08-12 Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors Ceased AU2019322325B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862765138P 2018-08-17 2018-08-17
US62/765,138 2018-08-17
PCT/IB2019/056847 WO2020035779A1 (en) 2018-08-17 2019-08-12 Urea compounds and compositions as smarca2/brm atpase inhibitors

Publications (2)

Publication Number Publication Date
AU2019322325A1 AU2019322325A1 (en) 2021-02-18
AU2019322325B2 true AU2019322325B2 (en) 2022-01-20

Family

ID=68072895

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019322325A Ceased AU2019322325B2 (en) 2018-08-17 2019-08-12 Urea compounds and compositions as SMARCA2/BRM ATPase inhibitors

Country Status (21)

Country Link
US (2) US11958846B2 (cg-RX-API-DMAC7.html)
EP (2) EP4219488A1 (cg-RX-API-DMAC7.html)
JP (1) JP7328323B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210047313A (cg-RX-API-DMAC7.html)
CN (2) CN112585136B (cg-RX-API-DMAC7.html)
AU (1) AU2019322325B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021002632A2 (cg-RX-API-DMAC7.html)
CA (1) CA3107097A1 (cg-RX-API-DMAC7.html)
CY (1) CY1126039T1 (cg-RX-API-DMAC7.html)
DK (1) DK3837256T3 (cg-RX-API-DMAC7.html)
ES (1) ES2946060T3 (cg-RX-API-DMAC7.html)
FI (1) FI3837256T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20230477T1 (cg-RX-API-DMAC7.html)
HU (1) HUE061963T2 (cg-RX-API-DMAC7.html)
LT (1) LT3837256T (cg-RX-API-DMAC7.html)
MX (1) MX2021001804A (cg-RX-API-DMAC7.html)
PL (1) PL3837256T3 (cg-RX-API-DMAC7.html)
PT (1) PT3837256T (cg-RX-API-DMAC7.html)
RS (1) RS64238B1 (cg-RX-API-DMAC7.html)
SI (1) SI3837256T1 (cg-RX-API-DMAC7.html)
WO (1) WO2020035779A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12282014B2 (en) 2015-11-19 2025-04-22 Dana-Farber Cancer Institute, Inc. Methods of identifying compounds that interfere with ERG-driven misguidance of BAF complexes in TMPRSS2-ERG driven prostate cancers
EP3746124A4 (en) 2018-01-30 2021-10-27 Foghorn Therapeutics Inc. COMPOUNDS AND THEIR USES
CN112585136B (zh) 2018-08-17 2024-06-25 诺华股份有限公司 作为smarca2/brm atp酶抑制剂的脲化合物和组合物
US12473334B2 (en) 2018-10-17 2025-11-18 Dana-Farber Cancer Institute, Inc. SWI/SNF family chromatin remodeling complexes and uses thereof
US12509453B2 (en) 2019-01-29 2025-12-30 Foghorn Therapeutics Inc. BRM/BRG1 inhibitors and uses thereof
US12384776B2 (en) 2019-01-29 2025-08-12 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2021155264A1 (en) 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2021155262A1 (en) 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
US12383555B2 (en) 2020-05-20 2025-08-12 Foghorn Therapeutics Inc. Methods of treating cancers
CN112979646B (zh) * 2021-03-08 2022-01-14 北京富龙康泰生物技术有限公司 一种咪唑并吡啶类衍生物
US12606553B2 (en) 2021-03-09 2026-04-21 Foghorn Therapeutics Inc. Crystalline forms, compositions containing same, and methods of their use
EP4734993A2 (en) * 2023-06-30 2026-05-06 Dana-Farber Cancer Institute, Inc. Methods for sensitizing drug-resistant cancer cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1256574A1 (en) * 2000-02-01 2002-11-13 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
US6863647B2 (en) * 1998-10-30 2005-03-08 Pharmacia & Upjohn S.P.A. 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2779780A (en) 1955-03-01 1957-01-29 Du Pont 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
US2871243A (en) * 1956-10-26 1959-01-27 May & Baker Ltd 5-amino-3-methyl-isothiazole and process
AUPP003197A0 (en) 1997-09-03 1997-11-20 Fujisawa Pharmaceutical Co., Ltd. New heterocyclic compounds
JP2002532415A (ja) 1998-12-16 2002-10-02 ワーナー−ランバート・カンパニー Mek阻害剤による関節炎の治療
AU7349801A (en) 2000-07-19 2002-01-30 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
US20020173507A1 (en) 2000-08-15 2002-11-21 Vincent Santora Urea compounds and methods of uses
US7304066B2 (en) 2001-05-24 2007-12-04 Bjoerkling Fredrik Pyridyl cyanoguanidine compounds
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
CA2478065C (en) 2002-03-08 2013-01-08 Eisai Co. Ltd. Macrocyclic compounds useful as pharmaceuticals
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
US20030236287A1 (en) 2002-05-03 2003-12-25 Piotrowski David W. Positive allosteric modulators of the nicotinic acetylcholine receptor
CA2744893A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as glucokinase activators
JP2006521345A (ja) 2003-03-28 2006-09-21 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー ニコチン性アセチルコリン受容体の正のアロステリック調節剤
MX2008002114A (es) 2005-07-21 2008-04-17 Ardea Biosciences Inc Inhibidores de n-(arilamino)-sulfonamida de mek.
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
US8455513B2 (en) * 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
BRPI0816769A2 (pt) 2007-09-12 2016-11-29 Hoffmann La Roche combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso
WO2009055730A1 (en) 2007-10-25 2009-04-30 Genentech, Inc. Process for making thienopyrimidine compounds
CN103463084A (zh) 2008-03-14 2013-12-25 大塚制药株式会社 制剂组合物在制备治疗以mmp-2及/或mmp-9为起因的肺气肿的药物中的应用
CN103880737A (zh) * 2014-02-27 2014-06-25 浙江泰达作物科技有限公司 1-(2-氯-4-吡啶基)-3-苯基脲的制备方法
DK3169671T3 (da) 2014-07-17 2019-09-23 Sunshine Lake Pharma Co Ltd 1-(5-(tert.-butyl)isoxazol-3-yl)-3-(4-((phenyl)ethynyl)phenyl)ureaderivater og relaterede forbindelser som flt3-inhibitorer til behandling af kræft
MA41598A (fr) 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
CN105481723B (zh) 2015-04-29 2017-08-25 中国农业大学 一种非均相催化的烷基/苄基/芳基脲类化合物的制备方法
WO2018187414A1 (en) 2017-04-05 2018-10-11 The Regents Of The University Of California Inhibitors of mtor-rictor interactions
CN112585136B (zh) * 2018-08-17 2024-06-25 诺华股份有限公司 作为smarca2/brm atp酶抑制剂的脲化合物和组合物
WO2020126968A2 (en) 2018-12-20 2020-06-25 Bayer Aktiengesellschaft Urea derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6863647B2 (en) * 1998-10-30 2005-03-08 Pharmacia & Upjohn S.P.A. 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents
EP1256574A1 (en) * 2000-02-01 2002-11-13 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same

Also Published As

Publication number Publication date
US20240270738A1 (en) 2024-08-15
PL3837256T3 (pl) 2023-07-10
FI3837256T3 (fi) 2023-05-15
CN118666832A (zh) 2024-09-20
JP7328323B2 (ja) 2023-08-16
US20210323956A1 (en) 2021-10-21
EP3837256A1 (en) 2021-06-23
JP2021534147A (ja) 2021-12-09
HRP20230477T1 (hr) 2023-07-21
RS64238B1 (sr) 2023-06-30
SI3837256T1 (sl) 2023-07-31
AU2019322325A1 (en) 2021-02-18
CN112585136A (zh) 2021-03-30
CN112585136B (zh) 2024-06-25
LT3837256T (lt) 2023-06-12
EP4219488A1 (en) 2023-08-02
DK3837256T3 (da) 2023-05-30
ES2946060T3 (es) 2023-07-12
HUE061963T2 (hu) 2023-09-28
WO2020035779A1 (en) 2020-02-20
BR112021002632A2 (pt) 2021-05-11
US11958846B2 (en) 2024-04-16
KR20210047313A (ko) 2021-04-29
PT3837256T (pt) 2023-05-23
EP3837256B1 (en) 2023-03-08
CA3107097A1 (en) 2020-02-20
CY1126039T1 (el) 2023-11-15
MX2021001804A (es) 2021-04-19
US12358906B2 (en) 2025-07-15

Similar Documents

Publication Publication Date Title
KR20210047313A (ko) Smarca2/brm atp분해효소 저해제로서의 우레아 화합물 및 조성물
JP7560546B2 (ja) Shp2ホスファターゼ阻害剤並びにその作製方法及び使用方法
CN112996795B (zh) 作为src同源-2磷酸酶抑制剂的稠合的三环衍生物
KR102793719B1 (ko) 클라우딘6 항체 및 암치료방법
CN107793480B (zh) 一种抗cd19抗体及其制备方法和用途
EP3341379B1 (en) Inhibitors of ezh2
CA3056754A1 (en) Macrocyclic compounds as ros1 kinase inhibitors
CN110248937A (zh) 4,5-环状1,2,4-三唑酮
KR20070034487A (ko) 항il-13 항체, 항il-13 항체의 결정 및 이를 함유하는복합체
EP3004110A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
KR20210154158A (ko) 클라우딘-6 항체 및 약물 컨쥬게이트
KR20170076775A (ko) T 세포가 아닌 종양을 표적화하는 서바이빈 특이적인 t-세포 수용체
WO2022015670A1 (en) Pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cyclin-dependent kinase 2 inhibitors
KR20220107233A (ko) Car-nk 세포의 수득 방법
RU2798462C2 (ru) Соединения на основе мочевины и композиции на их основе в качестве ингибиторов атфазы smarca2/brm
CN110461323A (zh) 溶瘤病毒的增殖方法和抗肿瘤剂
Bernard et al. Helix-loop-helix (E2-5, HEB, TAL1 and Id1) protein interaction with the TCRalphadelta enhancers.
Kumar et al. Genomic organization and characterization of the promoter region of murine GSTM2 gene
WO2024035830A1 (en) Solid forms of a cdk inhibitor
CN119421877A (zh) 作为hset抑制剂的取代杂环化合物
HK40045602B (en) Urea compounds and compositions as smarca2/brm-atpase inhibitors
HK40045602A (en) Urea compounds and compositions as smarca2/brm-atpase inhibitors
US20250042918A1 (en) Compounds

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired